PSP selling stake in European rail lessor, investing in health-care technology company

The Public Sector Pension Investment Board is selling its stake in Alpha Trains, a Europe-based lessor of locomotives and passenger trains.

The PSP, which has invested in Alpha Trains since 2008, will sell its interest to the PGGM Infrastructure Fund, a Netherlands-based cooperative pension fund service provider.

“Alpha Trains is a unique business with a solid foundation and strong leadership team,” said Patrick Samson, senior managing director and global head of infrastructure investments at the PSP Investments, in a press release. “As the leading provider of flexible rail leasing solutions, we’re proud to have supported and contributed to their growth and success alongside our partners. We’re confident that PGGM Infrastructure Fund will be a positive addition to an already strong partnership, further supporting Alpha Trains’ potential.”

Read: PSP investing in U.K. real estate, OTPP issuing green bond

In other investment news, the PSP is the leading investor in a $190-million round of Series B financing for Valo Health, a U.S.-based health-care technology company.

Other investors participating in this round of funding include Atinum Investment, Flagship Pioneering, HBM Healthcare Investments, Invus Public Equities and Mirae Asset Capital Co., Ltd. The investment will support the continued discovery and development of therapeutic programs and will enable further build-out of Valo’s proprietary drug development platform, according to a press release.

“We’re entering a period of monumental growth and evolution in the biotech industry,” said Eduard van Gelderen, senior vice-president and chief investment officer at the PSP, in the release. “The PSP is keen to invest in innovative, cutting-edge technology that can improve people’s lives. We’re proud to support the extraordinary work that Valo is doing to identify ways to accelerate the creation of therapeutics for some of the world’s most complex diseases.”

Read: PSP invests in telecommunications, CPPIB in biopharmaceuticals